These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer. Tan YJ; Lee YT; Yeong KY; Petersen SH; Kono K; Tan SC; Oon CE Future Med Chem; 2018 Sep; 10(17):2039-2057. PubMed ID: 30066578 [TBL] [Abstract][Full Text] [Related]
51. Drug development: Mix and match. Scudellari M Nature; 2015 May; 521(7551):S12-4. PubMed ID: 25970452 [No Abstract] [Full Text] [Related]
52. [Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells]. Zhang YJ; Fang JY; Sun DF; Zhao SL; Shen GF; Zheng Q; Zhu HY Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):889-93. PubMed ID: 18478925 [TBL] [Abstract][Full Text] [Related]
53. Aurora kinases dawn as cancer drug targets. Sausville EA Nat Med; 2004 Mar; 10(3):234-5. PubMed ID: 14991042 [No Abstract] [Full Text] [Related]
54. Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress. Bahrami A; Amerizadeh F; ShahidSales S; Khazaei M; Ghayour-Mobarhan M; Sadeghnia HR; Maftouh M; Hassanian SM; Avan A J Cell Biochem; 2017 Aug; 118(8):1979-1983. PubMed ID: 28109136 [TBL] [Abstract][Full Text] [Related]
55. Revisiting the frontiers of pharmacogenomics of colon cancer. Falandry C; Bonnefoy M; Freyer G Pharmacogenomics; 2011 Sep; 12(9):1243-8. PubMed ID: 21919602 [No Abstract] [Full Text] [Related]
56. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
57. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Pandurangan AK Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112 [TBL] [Abstract][Full Text] [Related]
58. Colorectal cancer stem cells as biomarkers: where it all starts? Avital I; Summers TA; Steele SR; Waldman S; Nissan A; Bilchik AJ; Protic M; Man YG; Brücher BL; Stojadinovic A J Surg Oncol; 2013 Jun; 107(8):791-3. PubMed ID: 23512573 [No Abstract] [Full Text] [Related]
59. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063 [TBL] [Abstract][Full Text] [Related]
60. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy. Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]